Antimicrobial resistance threatens to undermine modern medicine. Bacteria evolve resistance to antibiotics faster than pharmaceutical companies develop new drugs. Australian research institutions are tracking resistance emergence, investigating transmission mechanisms, and exploring alternative treatment approaches. The work is urgent—without effective antibiotics, routine surgeries become dangerous and minor infections potentially fatal.

Surveillance Networks Track Resistance

Understanding antimicrobial resistance requires comprehensive monitoring across hospitals, clinics, and agricultural settings. The Australian Group on Antimicrobial Resistance (AGAR) coordinates surveillance, collecting isolates from hospitals nationwide and testing susceptibility to major antibiotics.

Recent data shows concerning trends. Carbapenem-resistant Enterobacterales—bacteria resistant to last-resort antibiotics—are detected increasingly frequently in Australian hospitals. While still rare compared to some countries, upward trends suggest that resistance mechanisms are spreading despite infection control measures.

Surveillance also reveals geographic variation. Capital city teaching hospitals see different resistance patterns than regional hospitals, reflecting different patient populations and antibiotic prescribing practices. This variation provides natural experiments helping researchers understand what factors drive resistance emergence and spread.

Genomic Surveillance Advances

Traditional resistance surveillance involves culturing bacteria and testing antibiotic susceptibility—a process taking days. Genomic sequencing can detect resistance genes within hours, enabling faster outbreak response and tracking resistance mechanism spread between patients and facilities.

The Doherty Institute in Melbourne has implemented genomic surveillance for selected pathogens, sequencing bacterial genomes from hospital infections to track transmission and identify resistance gene acquisition. The approach has proven valuable for outbreak investigation—genomic data definitively establishes whether infections are related through transmission or independent introductions.

Scaling genomic surveillance to routine use faces cost and infrastructure barriers. Sequencing equipment and bioinformatics expertise exist primarily in research settings and large teaching hospitals. Broader implementation requires making technology and analysis accessible to smaller regional laboratories.

Agricultural Antibiotic Use

Livestock production uses substantial antibiotics for growth promotion and disease prevention. This creates selection pressure for resistance that can spread to human pathogens through food contamination, environmental pathways, or direct transmission of resistance genes between bacteria.

Australian agriculture has voluntarily reduced antibiotic use over the past decade. Research at the University of Adelaide documents declining resistance in bacteria from Australian livestock compared to earlier surveillance. This suggests that reducing agricultural antibiotic use can slow resistance emergence.

However, imported food may carry antibiotic-resistant bacteria. Surveillance of retail meat has detected resistance genes in imported products at rates exceeding domestic production. Whether this represents meaningful risk to human health—versus simply indicating that resistance exists somewhere in food supply chains—requires further investigation.

Phage Therapy Development

Bacteriophages—viruses that infect bacteria—offer potential alternatives to antibiotics. Phages are highly specific, targeting particular bacterial species without affecting beneficial microbes. They also evolve alongside bacteria, potentially overcoming resistance limitations of static antibiotic molecules.

Researchers at Monash University are developing phage therapy approaches for infections resistant to conventional antibiotics. Early clinical trials show promise for treating chronic wound infections that don’t respond to antibiotics. The therapy appears safe, though effectiveness varies depending on bacterial strain and infection site.

Regulatory pathways for phage therapy remain unclear. Phages aren’t drugs in the traditional sense—they’re living entities that evolve. Existing pharmaceutical regulations don’t accommodate this biology well. International regulatory agencies are developing frameworks for phage therapy approval, but progress is slow.

Antibiotic Stewardship Programs

Reducing unnecessary antibiotic prescribing is essential for slowing resistance emergence. Stewardship programs in hospitals monitor prescribing, provide feedback to clinicians, and promote guidelines for appropriate antibiotic use.

Research at the University of Queensland evaluates stewardship program effectiveness. Studies show that well-designed programs reduce antibiotic use by 15-25% without worsening patient outcomes. The key is providing timely feedback to prescribers and making guidelines easy to follow at the point of care.

Community prescribing—GPs prescribing antibiotics for outpatient infections—represents a larger volume than hospital use but is harder to influence. Many GP antibiotic prescriptions are for viral infections where antibiotics provide no benefit. Changing prescribing behaviour requires convincing both clinicians and patients that antibiotics aren’t necessary for every infection.

New Antibiotic Discovery

Pharmaceutical companies have largely abandoned antibiotic development because economic returns are poor. Antibiotics are typically used for short periods, unlike chronic disease treatments that patients take for years. This makes antibiotic development financially unattractive despite urgent public health need.

Academic researchers are filling some gaps. The Community for Open Antimicrobial Drug Discovery at the University of Queensland screens compound libraries for antibiotic activity, then partners with external groups for further development. This open-source approach accelerates discovery by sharing results rather than competing for patent protection.

New antibiotic classes are desperately needed. Most antibiotics in current use were discovered decades ago. Bacteria have had time to evolve resistance mechanisms, and genetic sharing means resistance spreads between bacteria that haven’t personally encountered antibiotics. Genuinely novel antibiotic mechanisms could temporarily outpace resistance, buying time for other solutions.

Rapid Diagnostics Importance

A major driver of antibiotic overuse is diagnostic uncertainty. When clinicians can’t distinguish bacterial from viral infections or identify which bacteria are present, they prescribe broad-spectrum antibiotics that may be unnecessary or inappropriate.

Rapid diagnostic tests that identify pathogens and predict antibiotic susceptibility within hours rather than days would enable more targeted treatment. Several Australian research groups are developing point-of-care diagnostics using nucleic acid detection, biosensors, or microfluidics.

The challenge is matching laboratory test performance in practical clinical settings. Tests that work beautifully in research labs often perform poorly when used by busy clinicians with minimally processed samples. Bridging this gap requires design for usability alongside analytical performance.

Vaccine Development

Preventing infections reduces antibiotic use more effectively than any stewardship program. Vaccines against bacterial pathogens reduce disease burden and corresponding antibiotic consumption.

The Institute for Glycomics at Griffith University develops vaccines targeting bacterial surface carbohydrates. Their work has contributed to vaccines against pneumococcus and meningococcus—major bacterial pathogens causing infections that formerly required intensive antibiotic treatment.

Vaccines against additional pathogens could further reduce antibiotic dependence. Urinary tract infections, for example, cause enormous antibiotic consumption. An effective vaccine would transform treatment approaches, though developing vaccines against diverse bacteria causing these infections is technically challenging.

Environmental Resistance Reservoirs

Antibiotic resistance genes exist naturally in environmental bacteria. Wastewater treatment plants, where antibiotics, resistant bacteria, and diverse microbial communities mix, represent hotspots for resistance gene exchange. Discharge from these facilities can spread resistance into waterways.

UNSW researchers monitor resistance genes in Sydney waterways, documenting contamination downstream from wastewater treatment plants. Resistance gene concentrations decrease with distance from discharge points but remain detectable kilometres away. Whether this environmental resistance represents human health risk versus simply documenting that resistance exists somewhere in complex ecosystems remains debated.

Global Interconnection

Antimicrobial resistance is fundamentally a global problem. Resistant bacteria spread internationally through travel, trade, and migration. Australia’s geographic isolation provides some buffer but not complete protection.

Resistance patterns in Australia lag global hotspots by several years. Resistance mechanisms that emerged in India or Southeast Asia eventually appear in Australian hospitals as travellers or immigrants bring resistant bacteria. This predictability allows some preparation, but preventing importation entirely is impossible without unrealistic travel restrictions.

International collaboration on resistance surveillance and control is essential. Australia participates in WHO global surveillance networks and contributes to international research efforts. But coordination is challenging when nations face different resistance burdens and have varied capacity for surveillance and intervention.

The Long Game

Antimicrobial resistance won’t be solved quickly. It’s an evolutionary process that will continue as long as antibiotics are used. The goal is slowing resistance emergence and maintaining a toolkit of effective treatments despite bacterial evolution.

This requires sustained commitment to stewardship, surveillance, infection prevention, research, and international cooperation. Success means keeping resistance at manageable levels rather than eliminating it entirely—a realistic goal given biological constraints.

Australian research contributes meaningfully to global efforts while addressing local resistance challenges. The work spans basic microbiology, clinical medicine, public health, and even social science examining prescribing behaviours. Solving antimicrobial resistance requires all these perspectives working together over extended time frames.

Progress is incremental rather than dramatic. Resistance slows slightly here, new treatment shows promise there, surveillance catches outbreaks earlier. Collectively, these small advances maintain modern medicine’s ability to treat bacterial infections. The alternative—a post-antibiotic era where routine surgeries are deadly—is too dire to contemplate. The research continues, urgently but methodically, working to prevent that future.